A Double-Blind, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB680 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs AB-680 (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Arcus Biosciences
- 06 Sep 2019 Status changed from active, no longer recruiting to completed.
- 14 Aug 2019 Planned End Date changed from 26 Aug 2019 to 18 Aug 2019.
- 14 Aug 2019 Planned primary completion date changed from 26 Aug 2019 to 18 Aug 2019.